CytoDyn Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $276.4M
- Price
- $0.20
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 411.6K
About
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Quick stats
Shares outstanding1.4B
Computed float1.4B
Float / shares99.0%
Cash runway (months)3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001175680
Websitehttps://www.cytodyn.com
AI Summary
AI-generated1/17
minorneutralother
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Adaptin Bio (OTCQB: APTN) was among nine life-sciences companies presenting at the September 17 Virtual Investor Forum, and the recorded presentations are now available for on-demand viewing around the clock for 90 days.
The event featured live executive presentations from clinical-stage and commercial life-sciences companies, and select participants including Adaptin Bio are accepting one-on-one management meeting requests through September 22.
The release is issued by conference organizer Virtual Investor Conferences rather than by Adaptin Bio itself and contains no new financial, clinical, or corporate disclosure, making it routine investor-relations housekeeping rather than a market-moving event.